ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer

Permanent link
https://hdl.handle.net/10037/10191
DOI
https://doi.org/10.18632/oncotarget.9817
Thumbnail
View/Open
article.pdf (7.224Mb)
(PDF)
Date
2016-06-03
Type
Tidsskriftartikkel
Peer reviewed
Journal article

Author
Hansen, Ailin Falkmo; Sandsmark, Elise; Rye, Morten Beck; Wright, Alan J; Bertilsson, Helena; Richardsen, Elin; Viset, Trond; Bofin, Anna M.; Angelsen, Anders; Selnæs, Kirsten Margrete; Bathen, Tone Frost; Tessem, May-Britt
Abstract
TMPRSS2-ERG has been proposed to be a prognostic marker for prostate cancer. The aim of this study was to identify changes in metabolism, genes and biochemical recurrence related to TMPRSS2-ERG by using an integrated approach, combining metabolomics, transcriptomics, histopathology and clinical data in a cohort of 129 human prostate samples (41 patients). Metabolic analyses revealed lower concentrations of citrate and spermine comparing ERGhigh to ERGlow samples, suggesting an increased cancer aggressiveness of ERGhigh compared to ERGlow. These results could be validated in a separate cohort, consisting of 40 samples (40 patients), and magnetic resonance spectroscopy imaging (MRSI) indicated an in vivo translational potential. Alterations of gene expression levels associated with key enzymes in the metabolism of citrate and polyamines were in consistence with the metabolic results. Furthermore, the metabolic alterations between ERGhigh and ERGlow were more pronounced in low Gleason samples than in high Gleason samples, suggesting it as a potential tool for risk stratification. However, no significant difference in biochemical recurrence was detected, although a trend towards significance was detected for low Gleason samples. Using an integrated approach, this study suggests TMPRSS2-ERG as a potential risk stratification tool for inclusion of active surveillance patients.
Description
This article is also available at 10.18632/oncotarget.9817
This is an article under the terms of the Creative Commons Attribution 3.0 License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Publisher
Impact Journals
Citation
OncoTarget 2016
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (medisinsk biologi) [1103]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)